MA55609A - Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih - Google Patents

Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Info

Publication number
MA55609A
MA55609A MA055609A MA55609A MA55609A MA 55609 A MA55609 A MA 55609A MA 055609 A MA055609 A MA 055609A MA 55609 A MA55609 A MA 55609A MA 55609 A MA55609 A MA 55609A
Authority
MA
Morocco
Prior art keywords
codv
tri
treatment
specific
binding proteins
Prior art date
Application number
MA055609A
Other languages
English (en)
Inventor
Mangaiarkarasi Asokan
Christian Beil
Jochen Beninga
Joerg Birkenfeld
Mark Connors
Richard A Koup
Young Do Kwon
Peter D Kwong
Qingbo Liu
Paolo Lusso
John R Mascola
Gary J Nabel
Amarendra Pegu
Ercole Rao
Ronnie Wei
Ling Xu
Zhi-Yong Yang
Original Assignee
Sanofi Sa
The United States Of America Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, The United States Of America Represented By The Sec Dep Of Health And Human Services filed Critical Sanofi Sa
Publication of MA55609A publication Critical patent/MA55609A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA055609A 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih MA55609A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962831415P 2019-04-09 2019-04-09
EP19306312 2019-10-08

Publications (1)

Publication Number Publication Date
MA55609A true MA55609A (fr) 2022-02-16

Family

ID=70471109

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055609A MA55609A (fr) 2019-04-09 2020-04-08 Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih

Country Status (14)

Country Link
EP (1) EP3953384A1 (fr)
JP (1) JP2022526826A (fr)
KR (1) KR20210149796A (fr)
CN (1) CN114096561A (fr)
AU (1) AU2020273156A1 (fr)
BR (1) BR112021020346A2 (fr)
CA (1) CA3136147A1 (fr)
CO (1) CO2021014988A2 (fr)
IL (1) IL286932A (fr)
MA (1) MA55609A (fr)
MX (1) MX2021012384A (fr)
SG (1) SG11202111011SA (fr)
TW (1) TW202104274A (fr)
WO (1) WO2020210386A1 (fr)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480572B1 (fr) 2009-09-25 2019-01-30 The United States of America, as represented by The Secretary, Department of Health and Human Services Anticorps neutralisants dirigés contre le vih-1 et utilisation associée
WO2012154312A1 (fr) 2011-05-09 2012-11-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisants anti-vih-1 et leur utilisation
WO2013070776A1 (fr) 2011-11-07 2013-05-16 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps neutralisant la gp41 et leur utilisation
CN104271597B (zh) 2011-12-08 2018-05-25 美国政府(由卫生和人类服务部的部长所代表) Hiv-1的中和抗体及其用途
WO2013163427A1 (fr) 2012-04-25 2013-10-31 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Anticorps pour traiter les infections par le vih-1
WO2017011414A1 (fr) * 2015-07-10 2017-01-19 Duke University Molécules bispécifiques comprenant un bras dirigé contre l'enveloppe du vih-1
PL3365366T3 (pl) 2015-10-25 2022-01-31 Sanofi Trójspecyficzne i/lub trójwalentne białka wiążące do zapobiegania lub leczenia zakażenia HIV
EP3443006B1 (fr) 2016-04-13 2023-08-02 Sanofi Protéines de liaison trispécifiques et/ou trivalentes

Also Published As

Publication number Publication date
CO2021014988A2 (es) 2022-01-17
MX2021012384A (es) 2022-02-21
SG11202111011SA (en) 2021-11-29
KR20210149796A (ko) 2021-12-09
IL286932A (en) 2021-10-31
CA3136147A1 (fr) 2020-10-15
CN114096561A (zh) 2022-02-25
AU2020273156A1 (en) 2021-12-02
BR112021020346A2 (pt) 2021-12-07
WO2020210386A1 (fr) 2020-10-15
JP2022526826A (ja) 2022-05-26
TW202104274A (zh) 2021-02-01
EP3953384A1 (fr) 2022-02-16

Similar Documents

Publication Publication Date Title
FR22C1063I1 (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
EA201891028A1 (ru) Триспецифические и/или тривалентные связывающие белки для предупреждения или лечения инфекции, вызываемой hiv
MA48772B1 (fr) Inhibiteurs de kras g12c et leurs procédés d'utilisation
EA201991697A1 (ru) Сульфоксиминовые ингибиторы гликозидазы
MA53937A (fr) Compositions comprenant des souches bactériennes
MA44659B1 (fr) Anticorps anti-tim-3 et compositions
MA50482A (fr) Dérivés cyclisés de sulfamoylarylamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
MA43763A (fr) Protéine f de pré-fusion du vrs soluble et stabilisée pour son utilisation dans la prophylaxie d'une infection vrs
MA38208B1 (fr) Inhibiteurs de bmi-1 pyrimidines inversés substitués
MA49131A (fr) Utilisation d'antagonistes de klk5 pour le traitement d'une maladie
MA55609A (fr) Protéines de liaison trispécifiques et/ou trivalentes utilisant un format de domaine croisé à double variable (codv) pour le traitement d'une infection par le vih
FR3084255B1 (fr) Souche de streptococcus thermophilus cnrz160 pour le traitement et la prevention de l'inflammation intestinale et des desordres associes, chez un individu
MA54936A (fr) Triamtérène ou nolatrexed destinés à être utilisés dans le traitement de la phénylcétonurie
MA53481A (fr) Méthodes et compositions pour le traitement de sujets ayant une polyarthrite rhumatoïde
MA54501A (fr) Nouvelles protéines de liaison spécifiques de folr1 pour le diagnostic et le traitement du cancer
WO2022023566A3 (fr) Anticorps anti-cd-3 pour le traitement du coronavirus
MA49635A (fr) Compositions comprenant du darunavir, du cobicistat, de l'emtricitabine et du ténofovir alafénamide pour une utilisation dans le traitement du vih
MA54512A (fr) Dérivés de la quinoléine destinés à une utilisation dans le traitement ou la prévention du cancer
MA45794A (fr) Système de marqueur pour confirmer l'exactitude de compositions et de formulations agrochimiques
FR3100128B1 (fr) Composition pharmaceutique destinée à inhiber l’infectiosité du VIH, à traiter le syndrome d’immunodéficience acquise (SIDA) et ses complications
MA52738A (fr) Méthodes de traitement de l'arthrite psoriasique
WO2019003150A3 (fr) Association, utilisations et schémas thérapeutiques
RU2014108627A (ru) Автоматический межсетевой экран
MA53734A (fr) Polynucléotides codant pour l'arginase 1 pour le traitement d'une déficience en arginase
WO2017093543A3 (fr) Composés antibactériens